share_log

Stephens & Co. Reiterates Overweight on Lifecore Biomedical, Maintains $11 Price Target

Benzinga ·  Mar 17, 2023 08:47

Stephens & Co. analyst Jacob Johnson reiterates Lifecore Biomedical (NASDAQ:LFCR) with a Overweight and maintains $11 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment